Pharmacotherapy of borderline states.
Our current state of knowledge regarding the pharmacologic management of BDs is at an early point in its evolution, exceeded only marginally by our ability to define the nosologic boundaries of these disorders. As the boundaries become better defined, especially those shared with the AD spectrum, and concurrently there is an effort to define nosologic subgroups based on differential drug treatment response, we gradually will be able to prospectively make better prescribing decisions and thereby reduce the trial-and-error aspect, with its potential for further sensitizing this population who already deal poorly with inconstancy.
Brinkley
J R
JR
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.
D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines; D001883:Borderline Personality Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D006801:Humans; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D011619:Psychotropic Drugs; D001569:Benzodiazepines; D016651:Lithium Carbonate